BioMarin Pharmaceutical Inc. Stock Forecast NASDAQ:BMRN

Price Target and Analyst Ratings

Most Recent Rating

On September 14, 2021 "SVB Leerink" gave "" rating for BMRN. The price target was set to $77.98.

Last 30 Days

Historical Ratings

Date	Rating	Action	Authority	Current Price	Target Price
2021-09-14		Reiterated by	SVB Leerink	$76.17	$77.98
2021-09-09	$86.00 - $96.00	Upgraded by	Stifel Nicolaus	$80.11	$76.70→1.4%
2021-09-07	$88.00	Reiterated by	Royal Bank of Canada	$77.81	$78.57→7.5%
2021-09-07	$152.00	Reiterated by	Wedbush	$77.81	$78.57→7.5%
2021-08-30	$141.00 - $152.00	Target Raised by	Wedbush	$83.27	$83.46→0.1%
2021-07-29	$141.00	Reiterated by	Wedbush	$78.51	$80.22+1.9%
2021-07-29	$112.00	Initiated by	Jefferies Financial Group	$78.51	$80.22+1.9%
2021-07-29	$87.00 - $88.00	Target Raised by	Royal Bank of Canada	$78.51	$81.07+3.0%
2021-07-29	$112.00 - $119.00	Target Raised by	Piper Sandler	$78.51	$78.73+0.5%
2021-07-16	$141.00	Reiterated by	Wedbush	$78.84	$79.53→0.1%
2021-07-11		Initiated by	SVB Leerink	$83.62	$83.62+0.8%
2021-07-02		Reiterated by	SVB Leerink	$85.47	$83.62+0.8%
2021-07-02	Buy	Reiterated by	SVB Leerink	$85.47
2021-06-29	Buy	Reiterated by	Wedbush	$83.46	$141.00
2021-04-28	Buy	Reiterated by	Wedbush	$80.46	$139.00
2021-04-26	Outperform	Initiated by	Credit Suisse Group	$81.16	$102.00
2021-04-26	Equal Weight	Target Lowered by	Morgan Stanley	$81.16	$85.00 → $82.00
2021-04-19	Equal Weight	Target Lowered by	Morgan Stanley	$79.59	$85.00 → $82.00
2021-03-23	Outperform	Reiterated by	Wedbush	$76.52	$139.00
2021-03-08	In-Line - Outperform	Upgraded by	Evercore ISI	$76.59	$90.00 → $100.00
2021-03-08	Buy	Target Lowered by	Canaccord Genuity	$76.59	$95.00 → $91.00
2021-03-01	Buy	Target Lowered by	Canaccord Genuity	$79.17	$95.00 → $91.00
2021-03-01	Outperform	Upgraded by	Evercore ISI	$79.17
2021-03-01	Buy	Reiterated by	Robert W. Baird	$79.17
2021-01-11	Positive - Outperform	Target Raised by	Robert W. Baird	$81.24	$100.00 → $110.00
2020-11-06	Outperform	Target Lowered by	SVB Leerink	$76.74	$113.00 → $108.00
2020-09-10	Buy	Reiterated by	Wedbush	$71.87
2020-09-10		Target Lowered by	Truist	$71.87	$130.00 → $125.00
2020-08-21	Equal Weight	Target Lowered by	Morgan Stanley	$75.03	$125.00 → $85.00
2020-08-20		Target Lowered by	Oppenheimer	$74.85	$116.00 → $88.00
2020-08-20		Target Lowered by	Truist	$74.85	$143.00 → $130.00
2020-08-20	Outperform - Market Perform	Reiterated by	William Blair	$74.85
2020-08-20	Buy	Target Lowered by	Canaccord Genuity	$74.85	$119.00 → $95.00
2020-08-20	Buy	Target Lowered by	Jefferies Financial Group	$74.85	$138.00 → $118.00
2020-08-19	Buy - Neutral	Downgraded by	Citigroup	$76.72
2020-08-19	Buy - Hold	Downgraded by	Stifel Nicolaus	$76.72	$127.00 → $100.00
2020-08-19	Outperform	Target Lowered by	SVB Leerink	$76.72	$140.00 → $113.00
2020-08-19	Buy	Reiterated by	Wedbush	$76.72	$136.00
2020-08-19	Outperform - Sector Perform	Downgraded by	Royal Bank of Canada	$76.72
2020-08-14		Target Raised by	Goldman Sachs Group	$118.16	$172.00 → $218.00
2020-08-06	Market Perform	Target Raised by	BMO Capital Markets	$119.65	$94.00 → $108.00
2020-08-05	Hold	Initiated by	Oppenheimer	$119.83	$116.00
2020-08-05	Buy	Reiterated by	Wedbush	$119.83	$146.00
2020-08-05		Target Raised by	Piper Sandler	$119.83	$120.00 → $133.00
2020-08-05		Target Raised by	Barclays	$119.83	$125.00 → $135.00
2020-08-05	Buy	Reiterated by	Credit Suisse Group	$119.83	$128.00
2020-08-05	Overweight	Target Raised by	JPMorgan Chase & Co.	$119.83	$140.00 → $156.00
2020-08-05	Outperform	Target Raised by	SVB Leerink	$119.83	$130.00 → $140.00
2020-07-28	Buy	Reiterated by	JPMorgan Chase & Co.	$122.83	$140.00
2020-07-27	Buy	Reiterated by	Wedbush	$124.00
2020-07-08	Overweight - Equal Weight	Downgraded by	Morgan Stanley	$128.73	$125.00
2020-07-06	Buy	Target Raised by	Citigroup	$127.71	$105.00 → $148.00
2020-06-21	Buy	Reiterated by	JPMorgan Chase & Co.	$124.12
2020-06-18	Performer	Target Raised by	Oppenheimer	$113.83	$88.00 → $95.00
2020-06-18	Buy	Reiterated by	Wedbush	$113.83	$145.00
2020-06-10	Buy	Target Raised by	Bank of America	$107.66	$120.00 → $130.00
2020-06-05		Target Raised by	Barclays	$105.80	$105.00 → $125.00
2020-06-01	Buy	Reiterated by	Credit Suisse Group	$107.39	$128.00
2020-05-10	Buy	Reiterated by	Cfra	$95.20	$115.00
2020-05-08		Target Raised by	Canaccord Genuity	$95.20	$108.00 → $119.00
2020-05-07	Buy	Reiterated by	Credit Suisse Group	$92.00	$128.00
2020-05-01	Buy	Reiterated by	William Blair	$88.12
2020-05-01	Buy	Reiterated by	Canaccord Genuity	$88.12	$108.00
2020-05-01	Outperform	Reiterated by	Wedbush	$88.12	$145.00
2020-04-30	Hold	Reiterated by	Oppenheimer	$92.02	$88.00
2020-04-30	Outperform	Target Lowered by	Credit Suisse Group	$92.02	$131.00 → $128.00
2020-04-30	Buy	Target Lowered by	SunTrust Banks	$92.02	$110.00 → $109.00
2020-04-30	Hold	Reiterated by	Nomura	$92.02	$77.00

BMRN Stock Trend

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled.

Given the current short-term trend, the stock is expected to fall -5.50% during the next 3 months and, with a 90% probability hold a price between $69.11 and $79.66 at the end of this 3-month period.

WARNING: Trend forecast is still in the development phase and should be used with caution. Some cases might produce unexpected results such as negative prices at the end of the trend.

Data

Date	Bottom	Mid	Top
2021-09-22	$73.06	$78.64	$84.22
2021-09-23	$72.98	$78.56	$84.14
2021-09-24	$72.90	$78.48	$84.06
2021-09-27	$72.82	$78.40	$83.98
2021-09-28	$72.74	$78.32	$83.90
2021-09-29	$72.67	$78.25	$83.83
2021-09-30	$72.59	$78.17	$83.75
2021-10-01	$72.51	$78.09	$83.67
2021-10-04	$72.43	$78.01	$83.59
2021-10-05	$72.36	$77.93	$83.51
2021-10-06	$72.28	$77.86	$83.44
2021-10-07	$72.20	$77.78	$83.36
2021-10-08	$72.12	$77.70	$83.28
2021-10-11	$72.04	$77.62	$83.20
2021-10-12	$71.97	$77.55	$83.12
2021-10-13	$71.89	$77.47	$83.05
2021-10-14	$71.81	$77.39	$82.97
2021-10-15	$71.73	$77.31	$82.89
2021-10-18	$71.65	$77.23	$82.81
2021-10-19	$71.58	$77.16	$82.74
2021-10-20	$71.50	$77.08	$82.66
2021-10-21	$71.42	$77.00	$82.58
2021-10-22	$71.34	$76.92	$82.50
2021-10-25	$71.26	$76.84	$82.42
2021-10-26	$71.19	$76.77	$82.35
2021-10-27	$71.11	$76.69	$82.27
2021-10-28	$71.03	$76.61	$82.19
2021-10-29	$70.95	$76.53	$82.11
2021-11-01	$70.88	$76.45	$82.03
2021-11-02	$70.80	$76.38	$81.96

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary syn... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!